Reactivity towards TCR peptides plays an important role in the regulation of several experimental autoimmune diseases. In a previous paper, we showed the TCRAV11 usage by an arthritogenic T cell clone isolated from a rat with adjuvant arthritis (AA). Moreover, we identified three immunogenic peptides in AV11: AV11 24-40, 41-55 and 66-80. In the present study, we show that T cells directed towards all three epitopes are part of the immune repertoire. The strongest delayed-type hypersensitivity (DTH) reaction was observed against the peptide derived from the third framework region, peptide AV11 66-80. DTH reactions to this peptide were detectable in naive rats and increased significantly after AA induction. Interestingly, modulation of the AV11 66-80 T cell response by nasal AV11 66-80 administration resulted in reduced DTH responses and in a strong inhibition of AA. These findings suggest that during the natural course of AA, T cells directed towards the third framework region of AV11 do not have a disease regulatory function, but instead play a role in the deterioration of AA.
Introduction
In autoimmune diseases, on the one hand, pathogenic selfregion of BV8S2 prevented the induction of both EAE and CIA in mice (10) . reactivity of T cells plays an important role, while, on the other hand, self-reactivity is needed to regulate auto-aggressive
The usage of TCR AV regions in experimental autoimmune diseases is less well documented. Previously, we showed the responses (1) . It has been shown that vaccination with modified auto-aggressive T cells protected against adjuvant usage of AV11 by an arthritogenic T cell clone (A2b) specific for heat shock protein 60 (13). This AV11 sequence contains arthritis (AA) and experimental autoimmune encephalomyelitis (EAE) (2, 3) . This suggested the activation of a T cell-specific a number of immunogenic regions as determined by immunization with overlapping peptides. Furthermore, T cell lines regulatory T cell population. Indeed, anti-TCR-specific T cell responses were detected during the natural course of several reactive to these peptides recognized the recombinant AV11 protein (13). Interestingly, in SWR and DBA/1 mice, two autoimmune diseases (4) (5) (6) (7) . Moreover, it has been shown that T cells reactive to epitopes derived from the TCR of polymorphisms in the AV11 gene have been observed to be associated with resistance to CIA induction (12,14). Moreover, pathogenic T cells play a role in the regulation of autoimmunity (7) (8) (9) (10) . These findings indicate that although TCR-derived vaccination with recombinant TCR AV11 decreased the arthritis incidence in CBA/1 mice (15). peptides are self-antigens, clonal deletion of TCR peptidespecific T cells in the thymus is not complete and that such
In the present paper, the AA model was used to study naturally occurring T cell reactivity towards the AV11 immunocells are activated during autoimmune diseases. Furthermore, in the experimental autoimmune models EAE and collagengenic regions. The strongest T cell reactivity was observed with a peptide derived from the third framework region of induced arthritis (CIA), it appeared that autoreactive T cells used predominantly BV8S2 (TCR V β 8.2) (11, 12) . Interestingly, AV11, AV11 66-80. Interestingly, nasal administration of AV11 66-80 led to a significant reduction of AV11 66-80-specific immunization with a peptide derived from the third framework DTH reactions during AA and to a significant inhibition of T cell proliferation assay disease. These data suggest that AV11 66-80-specific T cells Three days after the last nasal peptide administrations, rats play a role in the enhancement rather than in the downwere sacrificed, and the inguinal, popliteal and mandibular regulation of the arthritic process.
lymph nodes, and the spleen were isolated. Proliferation of 2ϫ10 5 Hercules, CA). Rats were lightly anesthetized with ether and 10 µl of 10 µg/µl peptide in PBS was administered nasally using a micropipette. This was done on days -15, -11, -7 and -3 Results preceding the induction of arthritis or EAE or the isolation of Natural processing and presentation of TCR AV11 epitopes spleen and mandibular lymph nodes.
during AA Induction and clinical evaluation of AA and EAE
Previously, we have identified three immunogenic regions of the TCR α chain of A2b: AV11 26-40, 41-55 and 66-80 (13). AA was induced by intradermal injection in the base of the tail of 100 µl 5 mg/ml Mycobacterium tuberculosis (Mt, strain T cell responses, induced after immunization with synthetic peptides comprised of sequences derived from these H37Ra; Difco, Detroit, MI) emulsified in incomplete Freund's adjuvant (IFA; Difco). To measure DTH reactions after inducimmunogenic regions, appeared to be MHC class II restricted (13). These findings raised the question whether during AA tion of AA, rats were immunized with 10 mg/ml Mt. Rats were examined in a blind set-up for clinical signs of arthritis.
the AV11 peptides were naturally processed and presented in a MHC class II-restricted manner. To study this, we evaluSeverity of arthritis was scored by grading each paw from 0 to 4 based on swelling, erythema and deformation of the ated the presence of AV11-specific T cells after the onset of AA. 14 Days after AA induction, the three immunogenic AV11 joints as described earlier (18). EAE was induced by s.c. injection of 50 µl of a 1:1 emulsion of peptide MBP 72-85 (1 peptides were tested for DTH reactivity. As shown in Table 1 , all three AV11 peptides induced a significant DTH reaction, mg/ml) with 4 mg/ml Mt in IFA in each hind footpad. In a blind set-up, rats were examined for EAE and severity was scored whereas no DTH reaction was observed with a highly immunogenic control peptide. This indicated that AV11 T cell epitopes on a scale from 0 to 4: 0, no signs; 1, limp tail; 2, hind leg weakness; 3, paraplegia; 4, front and hind leg paralysis, are naturally processed and presented in vivo, and that AV11 specific T cells are part of the T cell repertoire. moribund condition. a AA and EAE were induced as described in Methods. b AV11 66-80 was applied nasally 4 times before disease induction. c 100 µl AV11 66-80 (1 mg/ml in PBS) was injected in ears of naive rats or of rats 9 days after disease induction. In the contra-lateral ear 100 µl PBS was injected. Data are presented as described for Table 1 in deterioration or amelioration of the arthritogenic process. To study this, we applied AV11 66-80 nasally 4 times at 3-day intervals before disease induction and investigated the AV11 MHC binding affinity of AV11 epitopes 66-80-specific DTH reaction 9 days after AA induction. As shown in Table 2 , nasal administration reduced the DTH Previously, we demonstrated that blocking with OX6 (anti-RT1.B L ) abrogated the proliferative response of AV11 response significantly to almost undetectable levels. Next, we evaluated the effect of nasal AV11 66-80 administration on 26-40-specific T cells, while OX17 (anti-RT1.D L ) inhibited AV11 41-55-and 66-80-specific T cell responses (13). Here, the development of AA. As a control, we used the OVA 323-339 peptide. The peptides were applied nasally 4 times at 3-we determined in a competitive peptide-MHC binding assay the MHC binding affinity of AV11 26-40 for RT1.B L , and of day intervals, starting 14 days before AA induction. Nasal administration of AV11 66-80 almost completely inhibited AV11 41-55 and 66-80 for RT1.D L . Figure 1 shows the competitive inhibition of binding of the biotinylated marker arthritis development, whereas administration of OVA 323-339 had no influence on AA development ( Fig. 2A) . As an peptides to purified MHC class II molecules by the addition of increasing concentrations of non-labeled AV11 peptides.
additional clinical parameter, the percentage of weight loss was evaluated. As shown in Fig. 2(B) , OVA 323-339-treated AV11 26-40, which induced only a mild DTH reaction, appeared to be a strong binder for RT1.B L (IC 50 16-32 µM).
animals had a marked weight loss during active arthritis, while the AV11 66-80-treated animals only gained weight. To test Both AV11 41-55 and 66-80 induced a strong DTH reaction, and appeared to be a strong RT1.D L binder (IC 50 8-16 µM) whether the disease inhibitory effect of AV11 66-80 was ( Fig. 4a) . However, in the spleen, peptide-specific proliferative responses were detected (Fig. 4b) . This indicated that nasal peptide administration led to a specific T cell activation and did not delete peptide specific T cells. specific for AA, we analyzed the effect of nasal peptide administration on the induction of EAE in Lewis rats. At first, we measured the presence of AV11 66-80-specific T cells Discussion during the onset of EAE, as EAE is induced in the presence of the same adjuvant used for AA induction (Mt/IFA). As
In this paper, we report that T cells specific for three peptides derived from the AV11 region of an arthritogenic T cell clone shown in Table 2 , a strong DTH response was detected during the onset of EAE. Interestingly in contrast to the are naturally present in the T cell repertoire of Lewis rats, as measured by DTH reactions during AA. The peptide AV11 effect on AA, nasal peptide administration did not effect the development of EAE (Fig. 3A and B) .
26-40 induced only a mild DTH reaction, while peptides AV11 41-55 and 66-80 induced strong DTH reactions after AA
No deletion of AV11 66-80-specific T cells after nasal adminis-
induction. AV11 41-55 is localized in the second CDR and it tration has been described that in multiple sclerosis patients, CDR2 peptides derived from various variable regions of the TCR β Since we observed a clear inhibition of AV11 66-80 DTH responses after nasal peptide administration, we analyzed chain appeared to be immunogenic (20) . Furthermore, a CDR2 peptide derived from VB8S2 was found to be naturally whether this was due to deletion of AV11 66-80-specific T cells. Therefore, 3 days after the last nasal administration processed during EAE and protected against EAE (4). Our AV11 41-55 data confirm the finding that CDR2 peptides are of AV11 66-80 or control peptide OVA 323-339, spleen and mandibular lymph nodes were isolated and tested in a in general immunogenic (20) . AV11 66-80 is localized in the third framework region of the proliferation assay. In the mandibular lymph nodes, no proliferative responses were detected to the administered peptides α chain. Interestingly, a polymorphism in this framework region sional APC (23) or in presentation of TCR peptides by MHC class II molecules on activated T cells (24).
To study the role of AV11 66-80-specific T cells during AA, we applied AV11 66-80 nasally before AA induction. This resulted in a strong inhibition of the AV11 66-80-specific DTH reaction and in protection against AA. The protection was specific, since nasal AV11 66-80 application could not protect against EAE. Moreover, we observed that 3 days after the last nasal peptide administration, a clear peptide specific proliferative response was present in the spleen. Although we cannot exclude that after AA induction, AV11 66-80-specific T cells were deleted, the proliferative response in the spleen directly after nasal administration argues against AV11 66-80-specific T cell deletion as the main protective mechanism. In several other autoimmune models, the induction of T regulation of autoimmune diseases (30-32), it could well be possible that nasal AV11 66-80 administration led to enhanced activation of the already pre-existing regulatory T cell response. However, the reduction of the naturally occurring of AV11 was suggested to play an essential role in resistance and susceptibility to arthritis induction (14). Moreover, it has AV11 66-80 DTH response during AA after nasal AV11 66-80 administration indicated that nasal administration modulated been described that TCR peptides derived from the third framework region of both mouse and rat BV8S2 protected the natural AV11 66-80-specific T cell response. This finding, together with the finding that AV11 66-80-specific T cells were against experimental autoimmunity (6, 10) .
The observation that AV11-specific T cells were present in already activated before the clinical onset of arthritis, suggests that the naturally occurring AV11 66-80-specific T cell the immune repertoire indicated that these cells were not deleted in the thymus. T cell selection in the thymus is response during AA plays a role in the exacerbation or perpetuation of AA, rather than in the down-regulation of the controlled by the number of peptide-MHC complexes, the affinity of the peptides for the MHC molecules and the affinity disease process. This hypothesis is further substantiated by our recent findings indicating that 11 out of 36 rats immunized of the TCR for the MHC-peptide complex (21) . The mild DTH reaction to AV11 26-40 could be due to the rather high affinity with AV11 66-80 in a T h 1 skewing adjuvant (dimethyl-dioctadecyl ammonium bromide) developed arthritis (33) . Moreover, of the peptide for RT1.B L . However, AV11 66-80 induced the strongest DTH reaction and appeared to be a strong RT1.D L three out of five rats injected i.v. with AV11 66-80-specific T cells also developed arthritis, indicating the T cell-mediated binder. Therefore, the lack of deletion of these AV11-specific T cells should be due to either the low frequency of specific character of the AV11 66-80-induced arthritis. Enhancement of experimental autoimmune diseases after TCR peptide epitope-MHC complexes within the thymus or the relatively low TCR affinity for the specific peptide-MHC complexes. immunizations has also been described by others (34) (35) (36) . Yamamura and co-workers showed that an α chain TCR CDR3 Since AV11 66-80 showed the strongest DTH reaction at day 14 after disease induction, this peptide was selected for peptide derived from an encephalitogenic T cell clone did not only enhance MBP-or proteolipid protein-induced EAE, further study. Both the DTH reactions at days 9 and 14 were significantly increased as compared with naive animals. This but also AA (36). However, these findings and our findings are in contrast with data described by other groups, showing indicated that already during the induction phase of AA, before clinical signs of AA were visible, activation of TCR that deletion or neonatal tolerization of TCR-specific T cells or modulation of the TCR peptide-specific T h 1 response AV11 66-80-specific T cells had occurred. Taking into account the relatively high MHC binding affinity of the peptide, this towards a T h 2 response all resulted in exacerbation of the experimental autoimmune diseases EAE and diabetes (37-could imply that a relative low number of MHC-AV11 66-80 complexes is present in naive rats due to, for example, 41). There is no easy explanation why the outcome of TCRbased therapies is so variable. Differences could amongst crypticity of the epitope, while during the strong inflammatory process of AA, AV11 66-80 is unveiled. This would be in others be based on the activation of pre-existing versus induced TCR-specific T cells, the timing of the intervention, agreement with the observation by Di Rosa et al. showing that strong inflammatory processes can induce a change in the different model systems or the presence of MHC class II on rat T cells, which in contrast to mouse T cells express the processing machinery of antigen-presenting cells (APC) (22) . Alternatively, it is possible that in naive rats, due to the MHC class II (24).
In conclusion, we showed that AV11 peptide-specific T cells low frequency of AV11-bearing T cells, the number of specific MHC class II-AV11 66-80 complexes is low. During AA, an are part of the normal immune repertoire. Moreover, our data suggests that T cells specific for the third framework region expansion and subsequent turnover of AV11 ϩ T cells could result in uptake and presentation of AV11 peptides by profes-AV11 66-80 play a role in the deterioration of AA, rather 
